Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

New Novartis MS app will turn up the heat on its rivals

Patients can use SymTrac iPhone app to track symptoms and relapses on their current treatment

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

- PMLiVE

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

Changing the guard at Novartis’ Sandoz and Alcon units

Richard Francis joins from Biogen Idec and Kevin Buehler retires

Novartis building

Novartis replaces execs in Japan after investigation

Finds irregular practices in clinical trials programme

EU flag

Europe votes for greater clinical trial transparency

European Parliament passes new EU Clinical Trials Regulation

Novartis day

Novartis’ dual-action heart failure drug aces trial

Ends LCZ696 trial early on good results

Novartis building

FDA panel rejects Novartis’ heart failure hope serelaxin

Decision follows EMA knock back earlier this year

Novartis building

More bad news for Novartis on heart failure candidate

FDA reviewers recommend against approving serelaxin

Novartis day

Novartis’ German poster campaign to raise vaccination awareness

In-house designed work aims to educate public about meningococcal bacteria

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links